Montreal, Canada. May 23, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Joseph Walewicz, Vice President, Business and Corporate Development, will present an overview of the Company at the BioFinance 2012 Conference which will be held at the St. Andrew’s Club & Conference Centre in Toronto. Mr. Walewicz will be presenting on Wednesday, May 30 at 9:20 a.m.
BioFinance is the leading investor conference in Canada for the life sciences industry.
About MethylGene
MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is currently in Phase 2 trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.
Investor Relations Contact:
Joseph Walewicz, CFA
Vice President, Business & Corporate Development
MethylGene Inc.
Phone: 514-337-3333 ext. 373
ir@methylgene.com
www.methylgene.com
Thomas Fechtner
Vice President
The Trout Group LLC
Phone: 646-378-2931
tfechtner@troutgroup.com
www.troutgroup.com
